Bris­tol-My­ers of­fers some ea­ger­ly await­ed Check­mate-227 re­sults, but they're not chang­ing med­ical prac­tice -- yet

Ed­i­tor’s note: I asked lung can­cer ex­pert Jack West — a tho­racic on­col­o­gist at the Swedish Can­cer In­sti­tute at Swedish Med­ical Cen­ter — to take a look at the new da­ta from Bris­tol-My­ers Squibb from Check­mate-227. He makes some ex­cel­lent points about the way Bris­tol-My­ers pre­sent­ed this da­ta, with its broad de­f­i­n­i­tion of tu­mor mu­ta­tion bur­den as a bio­mark­er-de­fined end­point. The de­tailed com­ments are worth study­ing close­ly. It’s clear that Bris­tol-My­ers has a sig­nif­i­cant way to go be­fore they can con­vince prac­ti­tion­ers to change the way they treat lung can­cer.
— John Car­roll, Ed­i­tor

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER